NASDAQ$CDXS
Codexis Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Codexis reported strong financial results with R&D revenue increase, driven by Novartis and Takeda collaborations. 2020 financial guidance was withdrawn due to COVID-19 uncertainty.
Codexis reported $14.7 million in total revenues for Q1 2020, driven by a 26% year-over-year increase in R&D revenue. The company withdrew its 2020 financial guidance due to the uncertainty of the potential impact of the COVID-19 pandemic.
- Total revenues for the first quarter of 2020 were $14.7 million.
- R&D revenue increased by 26% to $9.6 million, driven by Novartis and Takeda collaborations.
- Product revenue was $5.1 million, a decrease compared to the previous year due to the timing of demand.
- Net loss for the first quarter of 2020 was $7.7 million, or $0.13 per share.
Headline financials
Revenue & EPS history
Codexis · Revenue · Quarterly
$14.7M
Forward guidance
Codexis withdrew its full year 2020 financial guidance due to the uncertain scope and duration of the COVID-19 pandemic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-0.4%
Avg return
Earnings day
-0.0%
Avg return
5 days after
+1.2%
Avg return
30 days after
48%
31 / 64 earnings
Positive
+33.9%
Q4 2025
Best reaction
-24.5%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.0% | -4.5% | -4.5% | |
| Q4 2025 | +33.9% | +15.7% | +76.4% | |
| Q3 2025 | -4.3% | -8.9% | -26.7% | |
| Q1 2025 | +1.2% | -0.8% | -9.7% | |
| Q4 2024 | -22.6% | -30.5% | -28.5% | |
| Q3 2024 | +9.0% | +19.0% | +42.7% | |
| Q2 2024 | -7.3% | -7.3% | -9.3% | |
| Q1 2024 | +26.0% | +13.5% | +8.7% | |
| Q4 2023 | +12.0% | +1.4% | -15.9% | |
| Q3 2023 | +16.3% | +4.8% | +48.8% | |
| Q2 2023 | -10.0% | -28.7% | -43.9% | |
| Q1 2023 | -8.1% | -24.4% | -35.7% | |
| Q4 2022 | -14.0% | -12.0% | -29.5% | |
| Q3 2022 | +10.3% | +4.9% | -1.4% | |
| Q2 2022 | +12.5% | +0.0% | -13.4% | |
| Q1 2022 | -9.2% | -17.3% | -20.9% | |
| Q4 2021 | +15.9% | +13.5% | +13.1% | |
| Q3 2021 | +18.8% | +18.7% | -3.7% | |
| Q2 2021 | +17.2% | +18.6% | +29.2% | |
| Q1 2021 | -5.0% | -9.9% | -0.4% | |
| Q4 2020 | -3.4% | -1.3% | -9.6% | |
| Q3 2020 | +2.3% | +9.1% | +23.9% | |
| Q2 2020 | +6.8% | +1.9% | -4.9% | |
| Q1 2020 | +2.3% | -2.9% | +2.2% | |
| Q4 2019 | -10.2% | -12.2% | -20.6% | |
| Q3 2019 | +10.1% | +11.4% | +10.0% | |
| Q2 2019 | -14.4% | -14.9% | -15.9% | |
| Q1 2019 | -5.7% | -3.3% | -11.9% | |
| Q4 2018 | -1.6% | -5.3% | -7.7% | |
| Q3 2018 | -7.2% | -9.0% | +25.3% | |
| Q2 2018 | +4.0% | +10.4% | +32.0% | |
| Q1 2018 | +9.1% | +14.2% | +25.9% | |
| Q4 2017 | +3.3% | +18.6% | -3.3% | |
| Q3 2017 | -3.1% | -8.5% | +6.2% | |
| Q2 2017 | +5.9% | +5.0% | +10.9% | |
| Q1 2017 | +1.1% | +0.0% | -2.2% | |
| Q4 2016 | +6.0% | +8.3% | +7.1% | |
| Q3 2016 | +2.2% | +10.8% | +8.6% | |
| Q2 2016 | +2.8% | +0.0% | -4.2% | |
| Q1 2016 | +2.5% | — | — | |
| Q4 2015 | -5.9% | — | — | |
| Q3 2015 | +2.9% | — | — | |
| Q2 2015 | -3.1% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q4 2014 | +5.4% | — | — | |
| Q3 2014 | -8.1% | — | — | |
| Q2 2014 | +7.1% | — | — | |
| Q1 2014 | +1.3% | — | — | |
| Q4 2013 | +3.1% | — | — | |
| Q3 2013 | -16.6% | — | — | |
| Q2 2013 | -12.5% | — | — | |
| Q1 2013 | +0.5% | — | — | |
| Q4 2012 | -8.5% | — | — | |
| Q3 2012 | -17.4% | — | — | |
| Q2 2012 | -24.5% | — | — | |
| Q1 2012 | -2.4% | — | — | |
| Q4 2011 | -8.7% | — | — | |
| Q3 2011 | +0.4% | — | — | |
| Q2 2011 | -9.3% | — | — | |
| Q1 2011 | -5.6% | — | — | |
| Q4 2010 | -1.5% | — | — | |
| Q3 2010 | -8.1% | — | — | |
| Q2 2010 | -5.5% | — | — | |
| Q1 2010 | -0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro